Equities

Cyclopharm Ltd

Cyclopharm Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)1.37
  • Today's Change0.015 / 1.11%
  • Shares traded4.05k
  • 1 Year change-33.17%
  • Beta0.6499
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.

  • Revenue in AUD (TTM)29.04m
  • Net income in AUD-9.32m
  • Incorporated2005
  • Employees87.00
  • Location
    Cyclopharm LtdUnit 4 / 1 The Crescent, KingsgroveSYDNEY 2208AustraliaAUS
  • Phone+61 29541-0411
  • Fax+61 29543-0960
  • Websitehttps://www.cyclopharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Mach7 Technologies Ltd30.01m-7.97m89.26m90.00--1.72--2.97-0.0331-0.03310.12460.2150.3864--3.64---10.26-6.48-12.71-7.5695.1994.91-26.56-17.84---55.080.0239---1.4626.28-660.45--33.06--
Austco Healthcare Ltd58.15m7.08m91.93m174.0011.222.059.831.580.02250.02250.18850.1231.092.564.59--13.2910.5818.4215.0952.7453.6512.178.701.7538.420.1483--38.2812.84213.3761.8623.85--
ImpediMed Ltd10.32m-19.79m107.25m83.00--2.63--10.39-0.0098-0.00980.00510.02010.17831.674.28124,325.30-34.20-44.56-37.62-51.7887.2783.08-191.78-220.516.16--0.0273---9.0419.953.56--6.90--
Respiri Ltd1.04m-7.13m117.48m2.00--39.57--113.12-0.007-0.0070.0010.00230.22160.0026.91---152.14-153.06-384.52-255.3469.98---686.48-617.730.3744-108.650.0423--56.850.1379-23.44------
SDI Ltd111.21m10.42m127.78m300.0012.261.368.751.150.08770.08770.93560.79060.81181.555.51--7.617.139.328.4062.0859.869.378.191.408.010.208746.683.116.9247.697.2911.964.72
EchoIQ Ltd44.50k-5.41m132.42m----17.87--2,975.67-0.0109-0.01090.000090.01260.0048--0.1208---58.04-65.22-76.45-83.27-----12,155.39-1,722.30----0.00---58.54-44.2334.56------
Optiscan Imaging Ltd1.16m-6.06m142.01m8.00--10.24--122.89-0.0074-0.00740.00140.01660.11380.30620.9086---59.70-49.52-70.78-58.8454.4616.53-524.45-312.657.45--0.0157---31.221.91-39.27--80.89--
Orthocell Ltd6.76m-7.18m149.45m----28.86--22.09-0.0356-0.03560.03350.02170.24061.479.37---25.55-28.99-30.96-34.0275.9571.10-106.16-242.964.11--0.1321--32.7947.88-14.93--20.63--
Cyclopharm Limited29.04m-9.32m150.59m87.00--3.17--5.19-0.0976-0.09760.30660.42780.51211.114.01333,756.60-16.43-12.60-19.97-14.9464.7770.20-32.08-25.473.42-37.570.1049--11.2215.5028.90---7.83-12.94
Genetic Signatures Ltd14.27m-17.86m156.54m----2.43--10.97-0.1124-0.11240.08640.28380.24531.023.20---30.70-11.57-34.00-12.6944.5655.89-125.15-25.418.76-509.340.0196---35.2914.72-27.11--50.98--
Medadvisor Ltd122.11m792.13k165.39m100.00197.373.2033.161.350.00150.00150.22280.09371.25--11.12--0.8137-15.721.37-24.6060.8159.350.6487-15.38--1.520.1964--24.6467.75107.01--77.57--
EMvision Medical Devices Ltd11.56m-2.73m165.47m----8.93--14.31-0.033-0.0330.14370.21680.6515-------15.38-47.89-20.97-59.47-----23.61-100.24---16.560.1354--62.9959.0629.48------
Anteris Technologies Ltd7.14m-87.90m190.26m1.00--30.46--26.65-5.04-5.040.41220.29550.23613.235.01---304.00-120.86-529.47-189.2768.4366.40-1,287.57-316.850.9233-132.480.3869--4.48-22.85-51.86--42.27--
4DMedical Ltd3.75m-35.98m199.11m----2.81--53.04-0.0972-0.09720.01010.17280.03530.28570.5844---33.79-39.81-41.36-50.9093.6967.64-958.34-1,941.161.74--0.0673--422.4640.12-14.36---1.77--
Aroa Biosurgery Ltd62.61m-9.63m217.29m261.00--2.52--3.47-0.028-0.0280.18210.250.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Imricor Medical Systems Inc1.28m-31.41m218.84m--------171.29-0.1842-0.18420.0073-0.04920.10410.85013.78---255.91-93.47-387.91-106.30-110.81-134.71-2,458.30-2,462.890.799-4.554.73---24.56-9.29-30.36---10.82--
Data as of Nov 18 2024. Currency figures normalised to Cyclopharm Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

15.61%Per cent of shares held by top holders
HolderShares% Held
Regal Funds Management Pty Ltd.as of 30 May 202412.00m10.80%
Investors Mutual Ltd.as of 31 Oct 20243.18m2.86%
Norges Bank Investment Managementas of 30 Jun 20242.16m1.94%
Karst Peak Capital Ltd.as of 23 Apr 20240.000.00%
More ▼
Data from 23 Apr 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.